Is There a CDK for BRCA2 Mutations?

We have obviously approval for allapative and talazapare for these BRCA mutations, so germline BRCA mutant tumors. And we can absolutely offer them part inhibitors for that, given the benefit we've seen in the Olympia trial in the adjuvant setting. We also have data in the metastatic setting for our metastatic patients in hormone receptor positive patients is about 3 to 5%, but certainly something we used before I think about chemotherapy. So my practice has shifted a little bit and I have now been offering ribosic lip as new start for a patient. Would I do that for a given patient and clinic is compassionate use right now? That's the question on